Search Results

You are looking at 1 - 10 of 282 items for :

  • "multicenter" x
Clear All
Free access

Kimberly Kamp, Brenda Gumz, Richard A Feelders, Dik J Kwekkeboom, Gregory Kaltsas, Frederico P Costa and Wouter W de Herder

progression following 177 Lu-octreotate therapy were included in this multicenter study. We retrospectively studied 24 patients with GEP-NETs, treated in three institutions in The Netherlands, Brazil, and Greece between 2010 and 2012. We retrospectively

Free access

Maria Chiara Zatelli, Mirella Torta, Antonette Leon, Maria Rosaria Ambrosio, Massimo Gion, Paola Tomassetti, Filippo De Braud, Gianfranco Delle Fave, Luigi Dogliotti and Ettore C degli Uberti

Group-author : On behalf of the Italian CromaNet Working Group

, an Italian multicenter observational study has been performed in a large series of gastroenteropancreatic (GEP) NET patients and healthy controls to assess the usefulness of CgA determination for the diagnosis of sporadic GEP NETs and to establish the

Restricted access

Esben Andreas Carlsen, Nicola Fazio, Dan Granberg, Simona Grozinsky-Glasberg, Hojjat Ahmadzadehfar, Chiara Maria Grana, Wouter T Zandee, Jaroslaw Cwikla, Martin A Walter, Peter Sandor Oturai, Anja Rinke, Andrew Weaver, Andrea Frilling, Sara Gritti, Anne Kirstine Arveschoug, Amichay Meirovitz, Ulrich Knigge and Halfdan Sorbye

often not feasible to perform in very rare diseases. Large retrospective datasets may then initially be the only way on which to base treatment decisions. In a large multicenter international cooperation, we therefore collected retrospectively the

Free access

Paola Sperone, Anna Ferrero, Fulvia Daffara, Adriano Priola, Barbara Zaggia, Marco Volante, Daniele Santini, Bruno Vincenzi, Giuseppe Badalamenti, Chiara Intrivici, Sabrina Del Buono, Silvia De Francia, Emmanouil Kalomirakis, Riccardo Ratti, Alberto Angeli, Luigi Dogliotti, Mauro Papotti, Massimo Terzolo and Alfredo Berruti

more efficacious than non-cisplatin-containing ones is being addressed by a large multicenter, multinational, randomized prospective study that is currently ongoing with the aim to compare efficacy of etoposide, doxorubicin, and cisplatin (EDP) plus

Free access

Tullio Florio, Federica Barbieri, Renato Spaziante, Gianluigi Zona, Leo J Hofland, Peter M van Koetsveld, Richard A Feelders, Günter K Stalla, Marily Theodoropoulou, Michael D Culler, Jesse Dong, John E Taylor, Jacques-Pierre Moreau, Alexandru Saveanu, Ginette Gunz, Henry Dufour and Philippe Jaquet

expression levels in somatotropinomas and non-functioning pituitary adenomas . European Journal of Endocrinology 156 65 – 74 . Warnet A Harris AG Renard E Martin D James-Deidier A Chaumet-Riffaud P 1997 A prospective multicenter trial of

Free access

Laetitia Dahan, Frank Bonnetain, Philippe Rougier, Jean-Luc Raoul, Eric Gamelin, Pierre-Luc Etienne, Guillaume Cadiot, Emmanuel Mitry, Denis Smith, Frédérique Cvitkovic, Bruno Coudert, Floriane Ricard, Laurent Bedenne, Jean-François Seitz and for the Fédération Francophone de Cancérologie Digestive (FFCD) and the Digestive Tumors Group of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)

series that included only 20 patients and no tumor response in the chemotherapy arm was observed ( Oberg et al . 1989 ). Therefore, because of the potential therapeutic effects of IFN in this disease, a randomized multicenter phase III trial was

Open access

Marcia S Brose, Johannes Smit, Chia-Chi Lin, Fabian Pitoia, Marc Fellous, Yoriko DeSanctis, Martin Schlumberger, Masayuki Tori and Iwao Sugitani

the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and progressive RAI refractory DTC. The efficacy and safety of sorafenib in RAI refractory DTC have been established in a multicenter, phase 3 DECISION trial involving 417

Free access

Larry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, Pharis Mohideen, Wouter W de Herder, Rudolf Arnold, Ke Hu, Yilong Zhang, Gareth Hughes, Lowell Anthony and Bertram Wiedenmann

profile, pasireotide may offer symptom reduction in patients who are inadequately controlled with octreotide LAR therapy. This paper presents results from a phase II, open-label, multicenter study designed to assess the efficacy and safety of pasireotide

Free access

P de Cremoux, I Bieche, C Tran-Perennou, S Vignaud, E Boudou, B Asselain, R Lidereau, H Magdelénat, V Becette, B Sigal-Zafrani and F Spyratos

of quantitative analyses of endocrine-related gene expression in breast cancer using real-time RT-PCR so that they can be used in prospective multicenter clinical trials. Quantitative RT-PCR assays may be particularly useful for quantitative

Open access

Andrew G Gianoukakis, Corina E Dutcus, Nicolas Batty, Matthew Guo and Mahadi Baig

(FDA) ( Worden 2014 ). More recently, based on the results of the randomized, double-blind, multicenter, phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT), the FDA approved lenvatinib for the treatment of locally